PGR and neoplasm: In daily routine diagnostics, surrogate (molecular-like) IBC subtyping is assessed using the immunohistochemical (IHC) expression of ER and PR, HER2 status [IHC and/or in situ hybridization (ISH)], the IHC expression of the proliferation marker Ki-67, and, depending on the classification definition used, tumor grade.